Toronto Dominion Bank increased its stake in shares of AbbVie Inc (NYSE:ABBV) by 10.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 652,814 shares of the company’s stock after buying an additional 62,877 shares during the period. Toronto Dominion Bank’s holdings in AbbVie were worth $58,012,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Formidable Asset Management LLC boosted its holdings in AbbVie by 0.3% in the 2nd quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock valued at $285,000 after purchasing an additional 10 shares during the period. WealthTrust Axiom LLC boosted its holdings in AbbVie by 0.3% in the 2nd quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock valued at $312,000 after purchasing an additional 15 shares during the period. Abner Herrman & Brock LLC boosted its holdings in AbbVie by 0.3% in the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock valued at $456,000 after purchasing an additional 18 shares during the period. St. Louis Trust Co boosted its holdings in AbbVie by 0.7% in the 2nd quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock valued at $248,000 after purchasing an additional 23 shares during the period. Finally, TRUE Private Wealth Advisors boosted its holdings in AbbVie by 0.6% in the 2nd quarter. TRUE Private Wealth Advisors now owns 4,814 shares of the company’s stock valued at $349,000 after purchasing an additional 27 shares during the period. 69.19% of the stock is owned by institutional investors and hedge funds.

A number of analysts have issued reports on ABBV shares. Societe Generale boosted their price objective on shares of AbbVie in a report on Tuesday, November 21st. Jefferies Group reissued a “buy” rating and issued a $107.00 price objective on shares of AbbVie in a report on Thursday, September 28th. Argus boosted their price objective on shares of AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a report on Friday, September 29th. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price objective for the company in a report on Tuesday, October 17th. Finally, BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 25th. Six analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie currently has an average rating of “Buy” and a consensus target price of $101.38.

In related news, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the completion of the transaction, the insider now directly owns 81,287 shares in the company, valued at approximately $7,360,537.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Severino sold 25,633 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the transaction, the executive vice president now owns 114,922 shares of the company’s stock, valued at $10,881,964.18. The disclosure for this sale can be found here. Insiders sold a total of 494,676 shares of company stock valued at $47,237,938 over the last 90 days. Corporate insiders own 0.23% of the company’s stock.

AbbVie Inc (ABBV) opened at $104.64 on Friday. The company has a market cap of $167,050.44, a P/E ratio of 25.46, a PEG ratio of 1.22 and a beta of 1.52. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 12-month low of $59.27 and a 12-month high of $104.87.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.21 EPS. sell-side analysts predict that AbbVie Inc will post 5.56 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.71 dividend. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a dividend yield of 2.71%. AbbVie’s payout ratio is presently 69.10%.

COPYRIGHT VIOLATION NOTICE: “AbbVie Inc (ABBV) Shares Bought by Toronto Dominion Bank” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/abbvie-inc-abbv-shares-bought-by-toronto-dominion-bank/1816784.html.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.